Hypotensive efficacy and cerebroprotective action of beta blocker metoprolol
Abstract
The aim of the study was to investigate hypotensive and cerebroprotective activity ofmetoprolol inpatients with essential arterial hypertension (EAR). In all participants, 24-hour blood pressure (BP) monitoring, cerebral perfusion scintigraphy, and cognitive function assessment were performed at baseline and after 6 weeks of treatment. After 6 weeks of therapy, according to 24-hour BP monitoring results, systolic and diastolic BP significantly declined. Cerebral blood flow substantially improved in parietal, frontal, and temporal areas. Cognitive function (memory, attention, thinking) also improved. Metoprolol optimally decreased BP and demonstrated cerebroprotective efficacy.
About the Authors
N. L. Afanasyeva
НИИ кардиологии ТНЦ СО РАМН
Russian Federation
Russian Federation
V. F. Mordovin
НИИ кардиологии ТНЦ СО РАМН
Russian Federation
Russian Federation
N. Yu. Efimova
НИИ кардиологии ТНЦ СО РАМН
Russian Federation
Russian Federation
G. V. Semke
НИИ кардиологии ТНЦ СО РАМН
Russian Federation
Russian Federation
I. Yu. Efimova
НИИ кардиологии ТНЦ СО РАМН
Russian Federation
Russian Federation
References
1. Верещагин Н.В., Моргунов В.А., Гулевская Т.С. Патология головного мозга при атеросклерозе и артериальной гипертонии. М.: Медицина, 1997. 287 с.
2. Глезер М.Г., Глезер Г.А. Справочник по фармакотерапии сердечно-сосудистых заболеваний. М.: Авиценна, 1996. 564 с.
3. Лурия А.Р. Высшие корковые функции человека и их нарушения при локальных поражениях мозга. МГУ, 1969. 504 с.
4. Сидоренко Б.А., Преображенский Д.В. Фармакотерапия гипертонической болезни. РМЖ. 1998; 6(19): 1228-37.
5. Lassen N.A., Andersen A.R., Fribrg L., et al. The Retention of [99m-Tc]-d, 1,-HMPAO in the Human Brain after Intracarotid Bolus injection: A Kinetic Analisis. // J. Cerebral. Blood Flow & Metab. 1988. V. 8. P. 13-22.
6. Ohkubo T., Imai Y., et al. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: The Ohasama Study.//J. Hypertens. l998. V. 16 (suppl. 2). P. S260.
7. Psaty В., Smith N.L., Siscovick D.S. Health outcomes associated with antihypertensive therapies used as first-line agents. An systematic review and meta-analysis. JAMA 1997; 277: 739-745.
8. Sans S., Kesteloof H., Kromhout D. The burden of cardiovascular diseases mortality in Europe. Eur. Heart. J. 1997; 1231-1248.
9. Warlow C.P. Epidemiology of stroke. Lancet 1998; 352 Suppl 11: 1-4.
10. Wechsler D. Wechsler Memory Scale-Revised. Manual. Psychological Corporation. New York; 1987.
11. Yonecura Y., Nishizawa S., Mukai T. SPECT with 99m-Tc-d, 1-hexamethyl propylene amine oxime (HM-PAO) compared with regional cerebral blood flow measured by PET. Effects of linearization. // J. Cerebral Blood Flow & Metab. 1988. V. 8. P. 82-89.
Review
For citations:
Afanasyeva N.L., Mordovin V.F., Efimova N.Yu., Semke G.V., Efimova I.Yu. Hypotensive efficacy and cerebroprotective action of beta blocker metoprolol. Russian Journal of Cardiology. 2005;(1):60-64. (In Russ.)
Views:
462
Email this article 